Skip to main content
OpenTrials
Completed

NCT Number: NCT02697032

FDHT PET and Bicalutamide in Metastatic Breast Cancer

Rationale: The purpose is to evaluate whether non-invasive in vivo imaging of androgen receptor (AR) presence in metastatic breast cancer patients by means of 18F-fluoro-dihydrotestosterone positron emission tomography (FDHT-PET) can be used to predict (early) treatment response to, and optimal dosing of, the anti androgen bicalutamide. The ultimate goal is to contribute to optimal selection of breast cancer patients for anti androgen treatment. Objective: Feasibility to detect a diffrence in uptake on 18F-FDHT scan after 6 weeks of treatment with bicalutamide in metastatic breast cancer patients. Secondary Objectives: to describe whether changes in 18F-FDHT tracer uptake after six weeks associates with response to bicalutamide, to describe whether changes in AR availability are different for breast cancer subgroups during treatment with bicalutamide and to describe whether 18F-FDHT tracer uptake is influenced by the amount of AR tumor expression. Study design: This is a single arm, one stage feasibility study, which will be executed in the University Medical Center Groningen, The Netherlands. The primary endpoint of the study is to evaluate the difference in 18F-FDHT uptake in tumor lesions after 6 weeks of bicalutamide treatment in patients with AR-positive metastatic breast cancer. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered. Study population: The investigators will include 20 postmenopausal metastatic breast cancer patients with an AR positive, HER2 negative tumor. Patients should be restaged clinically with bone scintigraphy and CT scan within a 6 week timeframe of the PET examinations. Intervention: All patients will receive a baseline FDHT-PET scan and start with bicalutamide treatment 150mg daily. During follow-up patients will receive one FDHT-PET scan after 6 weeks. Treatment with bicalutamide will continue until progression or unacceptable toxicity is encountered. Main study endpoint: The percent difference in 18F-FDHT uptake in tumor lesions after 6 weeks of monotherapy bicalutamide. A minimum decrease of 20% in 18F-FDHT uptake after 6 weeks compared to baseline uptake with an α of 0.05 and a power of 80%, is considered clinical significant.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

University Medical Center Groningen

Groningen, 9713 GZ, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A history of histological proven AR-positive (i.e. >10% staining), HER2-negative metastatic breast cancer (preferably assessment on fresh metastasis biopsy, alternatively archival metastasis biopsy)
  • Tumor progression after at least one line of systemic treatment
  • Measurable disease according to RECIST 1.1; or evaluable disease
  • Age ≥ 18 years
  • Postmenopausal status defined as one of the following:
  • Age ≥60 years
  • Previous bilateral oophorectomy
  • Age <60 years and amenorrhea for >12 months in the absence of interfering hormonal therapies (such as LH-RH agonists and ER-antagonists
  • Age <60 years using ER antagonists should have amenorrhea for >12 months and FSH >24U/L and LH>14U/L
  • Adequate hematological, renal and liver function as follows:
  • Absolute neutrophil count > 1.5 x 109/L
  • Platelet count >100 x 109/L
  • White blood cell count >3 x 109/L
  • AST and ALT <3.0 x upper limit of normal (ULN)
  • Alkaline phosphatase <2.5 x ULN
  • Creatinine clearance >50mL/min
  • Lipase/amylase <1/5 x ULN
  • Protrombin time, partial tromboplastin time and INR <1.5 x ULN
  • Written informed consent

Exclusion criteria

  • Unable to comply with the protocol
  • Evidence of central nervous metastases
  • Presence of life-threatening visceral metastases
  • Corrected QT interval (QTc) >500millliseconds at screening
  • Recent history of cardiac disease, including myocardial infarction, unstable angina pectoris or uncontrolled arrhythmia within 6 months prior to screening; or evidence of severe congestive heart failure with New York Heart Association severity classification > class I.
  • Recent history of trombo-embolic events within 6 months prior to screening
  • Hepatic impairment (Child-Pugh Class B or C)
  • Severe concurrent disease, infection, co morbid condition that, in the judgment of the investigator would make the patient inappropriate for enrollment
  • The concomitant use of strong CYP3A4 inhibitors (see table 1)
  • Previous anti-androgen treatment
  • Concurrent use of ER-directed anti hormonal therapies
  • Radiotherapy or major surgery within 4 weeks before baseline PET scanning

Treatment and study plan

bicalutamide

Drug

150mg

Other names: casodex

FDHT PET

Procedure

PET scan

Other names: 18F-FDHT PET

Primary outcomes

  1. quantify residual AR binding sites in metastatic breast cancer

    Time frame: 6 weeks

    To quantify residual AR binding sites in metastatic breast cancer after 6 weeks of treatment with bicalutamide.

Secondary outcomes

  1. determine whether changes in 18F-FDHT uptake

    Time frame: 6 weeks

    To determine whether changes in 18F-FDHT uptake after 6 weeks associates with response to bicalutamide.

  2. Influence amount of AR tumor expression

    Time frame: 6 weeks

    To determine whether 18F-FDHT tracer uptake is influenced by the amount of AR tumor expression.

  3. Difference in changes in AR availability

    Time frame: 6 weeks

    To determine whether changes in AR availability are different for breast cancer subgroups during treatment with bicalutamide

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Registry information

Official study title

FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Mar 3, 2016
Registry last updated
Nov 27, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.